Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,856 active trials61 approved drugs307 evidence items
- NCIt
- C156482
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07735962 | Prophylactic Subcutaneous Drainage After Gynecologic Oncology Midline Laparotomy(SCDRAIN-GO) | recruiting | N/A | 334 | Mahmut YassaOTHER_GOV | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03538665 | The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons(DETECT) | recruiting | — | 1,700 | University of Alabama at BirminghamOTHER | 1 | Jul 29, 2026 |
| clinicaltrials |
| NCT04113486 | Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations(ENRC) | recruiting | — | 400 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT05327465 | Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy | recruiting | N/A | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05665361 | Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | recruiting | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05756569 | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | recruiting | Phase 2 | 25 | Emory UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06545604 | Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer | recruiting | N/A | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT07106762 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 29, 2026 | clinicaltrials |
| NCT07200466 | Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation(ENDORISK-I) | recruiting | N/A | 735 | Radboud University Medical CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07518979 | EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer(MH-Penile-002) | recruiting | Phase 2 | 60 | Jiyan LiuOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07564232 | Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07728474 | LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder(LCS103) | recruiting | N/A | 60 | LifeBiotic Medical Research Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07733505 | Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?(NICE-C) | recruiting | Phase 1 | 10 | Odense University HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | recruiting | Phase 1 | 92 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05263050 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | recruiting | Phase 2 | 111 | Fox Chase Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07022483 | Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer | recruiting | Phase 3 | 710 | Daiichi SankyoINDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT07730203 | Photon-Counting Computed Tomography-Based Urethral Visualization Without Catheterization for Radiotherapy Planning: A Prospective Pilot Study Under ANTHEM(PURE-CT/ANTHEM) | recruiting | — | 20 | Istituto Clinico HumanitasOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07731828 | Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial | recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05404139 | Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)(DIRECT) | recruiting | Phase 2 | 352 | University Health Network, TorontoOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05460000 | A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy(N-Plus) | recruiting | Phase 2 | 640 | North Eastern German Society of Gynaecological OncologyOTHER | 6 | Jul 27, 2026 | clinicaltrials |
| NCT05611307 | Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors | recruiting | — | 150 | Indiana UniversityOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05838521 | A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer | recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06191133 | Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | recruiting | Phase 1 | 24 | Lindsay Ferguson, MDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06529809 | Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07043608 | Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases(ZAMBONI) | recruiting | Phase 2 | 20 | Kelly Fitzgerald, MDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07096999 | SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy | recruiting | — | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07407062 | A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy(FORCE) | recruiting | — | 200 | AbbVieINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07453459 | Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening | recruiting | N/A | 100 | Washington University School of MedicineOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | recruiting | Phase 1 | 174 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05113537 | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer(UPLIFT) | recruiting | Phase 1 / Phase 2 | 30 | Vadim S KoshkinOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06161506 | Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer | recruiting | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06856499 | Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer | recruiting | Phase 1 | 50 | University of Colorado, DenverOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06866964 | A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy(ASPIRE) | recruiting | Phase 2 | 35 | Wake Forest University Health SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07075939 | Centralization and Oncologic Outcomes in Ovarian Cancer(COOC - REMO) | recruiting | — | 200 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07169396 | Identifying Genetic Targets in Gynecological Tumors(GEN_EXP_CO2021) | recruiting | — | 180 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07281599 | Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer(EQUIP) | recruiting | N/A | 450 | QurasenseINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03854110 | A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine(MIROC-1) | recruiting | Phase 1 | 80 | Persevere Therapeutics Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05530655 | A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer | recruiting | Early Phase 1 | 30 | University of RochesterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06238713 | Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP) | recruiting | N/A | 480 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06405425 | A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 220 | MOMA TherapeuticsINDUSTRY | 3 | Jul 23, 2026 | clinicaltrials |
| NCT06795087 | Discharge Medication Use Post-Operatively in GU Cancer Patients | recruiting | — | 684 | Wake Forest University Health SciencesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06974110 | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 132 | MOMA TherapeuticsINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07042243 | The Florida ASCENT Study | recruiting | N/A | 100 | University of FloridaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07052214 | PSMA PET Combined With MRI for the Detection of PCa(BiPASS) | recruiting | Phase 3 | 338 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07711314 | Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy(ARMOR) | recruiting | Phase 2 | 48 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 23, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 30, 2026source: clinicaltrials